New hope for tough cancers: ZG006 trial opens for patients out of options
NCT ID NCT05978284
First seen Jan 10, 2026 · Last updated May 21, 2026 · Updated 19 times
Summary
This study tests a new drug called ZG006 in people with small cell lung cancer or neuroendocrine carcinoma who have run out of standard treatments or can't tolerate them. The goal is to find a safe dose and see if the drug can shrink tumors. About 54 adults aged 18 to 75 will take part in this early-phase trial.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SMALL CELL LUNG CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Henan Cancer Hospital
RECRUITINGZhengzhou, Henan, China
Conditions
Explore the condition pages connected to this study.